Kernal Biologics YC 申请

Summer 2020Active

Kernal Biologics 在 Summer 2020 批次的 Y Combinator 中作为一家 Healthcare 公司进行过。以下是：公司做什么、谁创立了它，以及其 YC 申请，按照真实 YC 表格逐题重建。

YC 批次: Summer 2020
行业: HealthcareTherapeutics
团队规模: 20
状态: Active
已发布: 2020

创始人

Yusuf ErkulFounder
Jeff OzdemirFounder
Burak YILMAZFounder

Kernal Biologics 做什么

Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS).

Kernal Biologics 的 YC 申请，重建版

Y Combinator 申请

Kernal Biologics，Summer 2020 期。来自公开数据的真实申请问题解答。

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Kernal Biologics

Describe what your company does in 50 characters or less.

mRNA 2.0 therapies targeting specific cells

What is your company going to make? Please describe your product and what it does or will do.

We're building selective mRNA-LNP immunotherapies that deliver mRNA precisely to specific immune cells. Our lead program, KR-402, targets T cells to program CAR-T therapies directly in the body and can deplete B cells within a week. This lets us treat cancer and autoimmune diseases with fewer off-target effects than current mRNA approaches.

Where do you live now, and where would the company be based after YC?

We live in Cambridge, MA, and Kernal is based there. After YC, we'd remain in Cambridge because that's where our team, science, and investors are concentrated.

Explain your decision regarding location.

Cambridge is a biotech hub with access to top academic talent and proximity to investors, which is critical for developing complex mRNA therapeutics. Being near MIT and Harvard also helps us recruit and collaborate on cutting-edge science.

21 更多回答在完整申请中

Founders, Progress, Idea, Equity, Curious, Batch Preference 包含在完整版中。创建免费账户即可在 YC Insights 中打开，紧邻每个其他 YC 批次。

查看完整申请

常见问题解答

这是 Kernal Biologics 的真实 YC 申请吗？

不是。Y Combinator 对提交的申请保密。这是重建版：使用 Kernal Biologics 的公开数据（发布笔记、创始人背景、产品描述）回答真实的 YC 表格问题。它展示了像 Kernal Biologics 这样的公司会如何向 YC 自我介绍，而不是他们提交的文本。

Kernal Biologics 是哪个 YC 批次的？

Kernal Biologics 是 Y Combinator Summer 2020 批次的成员。

谁创立了 Kernal Biologics？

Kernal Biologics 由 Yusuf Erkul, Jeff Ozdemir, Burak YILMAZ 创立。

Kernal Biologics 做什么？

Kernal is creating mRNA 2.0 therapies that work in specific cells

如何阅读完整的重建申请？

创建免费的 Round Funded 账户。YC Insights 中包含 Kernal Biologics 的完整 26 个问题的版本，以及其他所有 YC 批次的公司信息。